C43 Stock Chart & Stats
€60.40
€2.60(3.80%)
At close: 4:00 PM EDT
€60.40
€2.60(3.80%)
Day’s Range― - ―
52-Week Range€58.10 - €141.00
Previous CloseN/A
Volume100.00
Average Volume (3M)39.00
Market Cap
€973.99M
Enterprise Value€963.95
Total Cash (Recent Filing)€195.28M
Total Debt (Recent Filing)€4.33M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,543,522
10 Day Avg. Volume62
30 Day Avg. Volume39
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€122.20Price Target Upside102.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.13
Revenue Forecast (FY)€113.12M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal leverage and substantial equity provide financial resilience as COSMO develops and commercializes products. The company has greater capacity to fund research, partnerships, and operating needs internally, while low debt reduces interest burden and refinancing pressure during weaker earnings periods.
Licensing And Partnership-based Revenue ModelThe licensing model can extend COSMO's geographic reach without requiring it to fund every commercialization activity itself. Upfront payments, milestones, royalties, and partner-funded work may diversify monetization and create operating leverage when partnered products gain regulatory or market traction.
Focused Gastroenterology And Endoscopy SpecializationA concentrated focus on gastrointestinal diseases and endoscopy gives COSMO a defined therapeutic and clinical domain rather than a broad, unfocused portfolio. This specialization can help align product development, commercialization, and partnerships around identifiable medical needs over time.
Bears Say
Sharp Revenue ContractionThe sharp year-over-year revenue decline indicates that the latest operating scale is materially weaker than the prior year's performance. Unless revenue recovers, lower commercial volume can reduce funding available for development, weaken operating leverage, and make future earnings more volatile.
Negative Profitability And Inconsistent EarningsNegative 2025 margins and losses in multiple earlier years show that COSMO's earnings power is not consistently demonstrated across reporting periods. Uneven profitability makes planning and reinvestment less predictable, while weak operating leverage can magnify the effect of revenue fluctuations.
Cash Flow Turned NegativeThe reversal from strong positive cash generation to operating and free cash outflows raises questions about the sustainability of the current business model's self-funding capacity. Continued cash burn could require greater reliance on existing reserves or future financing to support operations and product investment.
COSMO Pharmaceuticals N.V. News
C43 FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was €58.10 and its highest was €141.00 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is €973.99M.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Mar 24, 2027 which is in 197 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2026. The company reported -€0.275 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.275.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. does not currently pay dividends.
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -€0.275 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went down -0.292%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in DE:C43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
C43 Stock 12 Month Forecast
Average Price Target
€122.20
▲(102.32% Upside)